ABOS · XBRL financial data

Acumen Pharmaceuticals financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ABOS's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	12,305	32,361	42,318	93,798	104,885
General and administrative	7,279	12,876	18,820	20,219	18,947
Total operating expenses	19,584	45,237	61,138	114,017	123,832
Operating income (loss)	(19,584)	(45,237)	(61,138)	(114,017)	(123,832)
Interest income	—	—	10,791	14,317	7,447
Interest expense	—	0	581	4,068	4,224
Other income (expense)	51	(11)	(83)	(151)	(266)
Income tax expense (benefit)	0	0	0	0	0
Net income (loss)	(100,606)	(42,856)	(52,371)	(102,329)	(121,335)
Earnings per share, basic USD per share	(5.02)	(1.06)	(1.08)	(1.71)	(2.00)
Earnings per share, diluted USD per share	(5.02)	(1.06)	(1.08)	(1.71)	(2.00)
Weighted average shares, basic thousands of shares	20,058	40,602	48,609	60,013	60,562
Weighted average shares, diluted thousands of shares	20,058	40,602	48,609	60,013	60,562

Fiscal years (ABOS's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	122,162	130,101	66,886	35,627	53,989
Marketable securities	72,075	47,504	176,636	135,930	62,876
Marketable securities, non-current	31,619	15,837	62,553	59,968	0
Prepaid and other current assets	4,424	2,724	3,093	6,749	5,387
Total current assets	198,661	180,329	246,615	178,306	122,252
Property and equipment, net	36	165	122	73	103
Right-of-use asset	0	105	381	266	140
Total assets	230,330	196,587	310,125	238,992	122,833
Accounts payable	1,088	1,640	1,379	5,648	554
Accrued liabilities	—	3,350	6,339	6,615	10,072
Total current liabilities	5,147	7,812	12,971	27,607	30,007
Lease liability, non-current	—	0	284	150	—
Total liabilities	5,147	7,812	43,152	57,176	52,403
Accumulated deficit	(127,571)	(170,427)	(222,798)	(325,127)	(446,462)
Total stockholders' equity	225,183	188,775	266,973	181,816	70,430
Total liabilities and equity	230,330	196,587	310,125	238,992	122,833
Common shares outstanding (cover page) thousands of shares	40,473	41,025	60,080	60,573	72,213

Fiscal years (ABOS's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(100,606)	(42,856)	(52,371)	(102,329)	(121,335)
Stock-based compensation	922	3,061	6,145	9,635	9,852
Net cash from operating activities	(17,961)	(35,153)	(43,064)	(86,215)	(115,538)
Net cash from investing activities	(104,120)	39,185	(171,671)	48,027	133,933
Proceeds from issuing common stock	168,556	3,792	121,904	7,938	0
Net cash from financing activities	200,466	3,907	151,753	6,928	(34)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.